Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C.E.R.A versus darbepoetin alfa for maintenance of hemoglobin in kidney transplant recipients with chronic renal anemia
2007-001905-10Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2007
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in anemia of chronic kidney disease comparing Pegzerepoetin alfa arm with Darbepoetin alfa arm (2 arms). Primary endpoints: Maintenance of hemoglobin concentration and Safety and tolerability. Started Jul 2007; status: completed.
02
Drugs
methoxy polyethylene glycol-epoetin betadarbepoetin alfa
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on 2007-001905-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001905-10.